Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Clinical trial NCT04130542 · COMPLETED
Trial details
- NCT number
- NCT04130542
- Sponsor
- Lyvgen Biopharma Holdings Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-31
- Primary completion
- 2025-12-31
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.